HPV vaccine linked to drop in cases of rare childhood disease

November 9, 2017

(HealthDay)—The human papillomavirus (HPV) vaccine, first developed to help guard against cervical cancer, also seems to protect against a rare, chronic childhood respiratory disease, a new study suggests.

It's believed that the —recurrent respiratory papillomatosis—occurs in children when HPV type 6 or 11 spreads from mother to child around the time of birth.

Some children develop wart-like, noncancerous growths in the respiratory tract, making it difficult to breathe. The condition can be life-threatening, and repeated surgeries are usually required to keep the airway clear.

In the United States, about 800 children develop recurrent respiratory papillomatosis each year. This results in annual medical costs of $123 million, according to a news release from the Journal of Infectious Diseases, which published the study on Nov. 9.

For the study, researchers analyzed Australian national data and found that new cases of recurrent respiratory papillomatosis in children fell from seven in 2012 to one in 2016.

None of the mothers of the children who were diagnosed with the disease between 2012 and 2016 had been vaccinated against HPV prior to their pregnancy.

The findings suggest that new cases of recurrent respiratory papillomatosis are disappearing in Australian because of the country's successful HPV vaccination program, the researchers said.

In Australia, about 86 percent of girls and 79 percent of boys aged 14 to 15 have received the first dose of the vaccine that protects against four cancer-causing types of HPV—types 6, 11, 16 and 18.

The statistics are not as encouraging in the United States, the researchers noted. Only 60 percent of teens aged 13 to 17 received one or more doses of the vaccine in 2016, according to the U.S. Centers for Disease Control and Prevention. Two doses of the vaccine are recommended for teens younger than 15 and three doses are recommended for those aged 15 through 26.

"This is a world-first finding of evidence that the HPV vaccine has actually prevented recurrent respiratory papillomatosis cases," said study author Dr. Julia Brotherton, a public health physician with the Victorian Cytology Service in Melbourne.

"It's really exciting that we finally have a way to prevent this terrible disease," she said in a journal news release. "It adds to the list of strong reasons why you as a parent should choose to vaccinate your child."

Wealthy nations with high HPV vaccination rates should conduct similar studies of their vaccination programs, Dr. Basil Donovan and Denton Callander, from the University of New South Wales in Sydney, Australia, wrote in an accompanying editorial.

"National and individual hesitancy remains common, and unless these hesitant countries are persuaded by the ever-expanding benefits of quadrivalent HPV vaccination, millions of dollars in health spending along with countless unnecessary episodes of disease and death will occur in the coming decades," they wrote.

Explore further: More U.S. teens getting vaccinated against HPV

More information: The U.S. National Institute on Deafness and Other Communication Disorders has more on recurrent respiratory papillomatosis.

Related Stories

More U.S. teens getting vaccinated against HPV

August 24, 2017
(HealthDay)—Six out of 10 U.S. parents are choosing to get their children vaccinated against the cancer-causing human papillomavirus (HPV), which is spread by sexual contact, federal health officials reported Thursday.

Whooping cough shot works, but many moms-to-be skip it: CDC

September 28, 2017
(HealthDay)—Tdap vaccination during pregnancy prevents whooping cough in about three-quarters of newborns—but only about half of mothers-to-be get the shot, a new U.S. study reveals.

Nearly half of U.S. men infected with HPV, study finds

January 19, 2017
(HealthDay)—Many American men are infected with the cancer-causing human papillomavirus (HPV), but unlike women, men are more likely to stay infected throughout their lives, a new study finds.

Virus-like particle vaccine protects against RSV vaccine-enhanced respiratory disease, study finds

October 23, 2017
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory disease that results when patients given an early form of a vaccine for respiratory syncytial ...

Many with work-related asthma not getting key vaccine

September 27, 2017
(HealthDay)—Only half of American adults with work-related asthma get the recommended vaccination against pneumococcal disease, a new study finds.

No increased risk of chronic fatigue syndrome after HPV vaccination

June 23, 2017
Girls receiving one or more doses of HPV vaccine have no greater risk of chronic fatigue syndrome/myalgic encephalomyelitis (CFS / ME) than unvaccinated girls. This is shown in a new major study from the Norwegian Institute ...

Recommended for you

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

Maternally acquired Zika immunity can increase dengue disease severity in mouse pups

November 14, 2018
To say that the immune system is complex is an understatement: an immune response protective in one context can turn deadly over time, as evidenced by numerous epidemiological studies on dengue infection, spanning multiple ...

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

Synthetic DNA-delivered antibodies protect against Ebola in preclinical studies

November 13, 2018
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...

Scientists illuminate causes of hepatitis B virus-associated acute liver failure

November 13, 2018
National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF)—a rare condition that can turn fatal within days without liver transplantation—results ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.